UCB (OTCMKTS:UCBJF) Sees Large Volume Increase – Still a Buy?

UCB SA (OTCMKTS:UCBJF) saw strong trading volume on Tuesday . Approximately 9,277 shares changed hands during mid-day trading, an increase of 1,063% from the previous session’s volume of 798 shares.The stock last traded at $263.3625 and had previously closed at $263.84.

Analysts Set New Price Targets

UCBJF has been the subject of several research analyst reports. Jefferies Financial Group upgraded UCB to a “hold” rating in a research report on Monday. Piper Sandler reissued a “neutral” rating on shares of UCB in a research note on Wednesday, July 22nd. Six research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, UCB presently has an average rating of “Moderate Buy”.

UCB Stock Performance

The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78. The firm’s fifty day moving average is $291.18 and its 200-day moving average is $299.23.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.